title: Unrelated donor bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria--successful treatment despite multiple transplant-related risk factors for hemolysis including major Kidd group incompatibility.
authors.forename: M
authors.initials: M
authors.lastname: Markiewicz
authors.forename: M
authors.initials: M
authors.lastname: Wojciechowska
authors.forename: I
authors.initials: I
authors.lastname: Wylezoł
authors.forename: K
authors.initials: K
authors.lastname: Woźniczka
authors.forename: S
authors.initials: S
authors.lastname: Giebel
authors.forename: J
authors.initials: J
authors.lastname: Wojnar
authors.forename: M
authors.initials: M
authors.lastname: Krawczyk-Kuliś
authors.forename: E
authors.initials: E
authors.lastname: Mendek-Czajkowska
authors.forename: J
authors.initials: J
authors.lastname: Hołowiecki
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D001787:Blood Group Incompatibility; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002066:Busulfan / Q000008:administration & dosage / Q000031:analogs & derivatives; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood / Q000150:complications / Q000628:therapy*; D006461:Hemolysis; D006648:Histocompatibility; D006801:Humans; D007667:Kidd Blood-Group System / Q000097:blood; D019520:Living Donors; D008297:Male; D012307:Risk Factors; D019172:Transplantation Conditioning / Q000379:methods
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007667:Kidd Blood-Group System; C018404:treosulfan; D002066:Busulfan